Vimian Group AB
STO:VIMIAN
Gross Margin
Vimian Group AB
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| SE |
V
|
Vimian Group AB
STO:VIMIAN
|
17.2B SEK |
69%
|
|
| JP |
|
Hoya Corp
TSE:7741
|
6.4T JPY |
86%
|
|
| CH |
|
Alcon AG
SIX:ALC
|
33.9B CHF |
54%
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
132.9B DKK |
68%
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
9.9B USD |
70%
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
5.3B CHF |
39%
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.7B GBP |
56%
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
43.8B CNY |
70%
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
5B USD |
48%
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.1B USD |
60%
|
|
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
650.7B JPY |
66%
|
Vimian Group AB
Glance View
Vimian Group AB is a relatively new player making waves in the veterinary and animal health industries. Founded in Sweden, Vimian is structured as a conglomerate composed of specialized subsidiaries focused on different niche markets within veterinary services, diagnostics, and technology. This strategic structure enables the company to operate across various segments such as Veterinary Services, Specialty Pharma, MedTech, and Diagnostics, achieving a holistic approach to animal healthcare. By acquiring and partnering with innovative companies globally, Vimian capitalizes on synergies and cross-market opportunities, ensuring a competitive edge in each of its operational fields. The company’s diverse portfolio allows it to cater not only to pet owners and veterinary professionals but also to livestock industries, ensuring comprehensive coverage in the growing market of animal welfare and health. Vimian’s revenue streams are multi-faceted, generated from a blend of product sales, subscriptions, and service fees. For instance, within its Specialty Pharma segment, the company develops and sells pharmaceutical products designed to treat common and specialty conditions in animals, thus generating continuous revenue from veterinary practices worldwide. In the MedTech segment, Vimian offers cutting-edge medical devices and equipment, enhancing veterinary surgical and diagnostic capabilities, which drives sales. Meanwhile, their Diagnostics division provides innovative testing solutions that help veterinarians identify and treat animal diseases accurately, offering another lucrative revenue stream. This multi-pronged business model not only mitigates risk through diversification but also positions Vimian as a key player in meeting the rapidly evolving demands of animal health and care.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Vimian Group AB's most recent financial statements, the company has Gross Margin of 68.7%.
You don't have any saved screeners yet